Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
Blog Tag

clinical trials

4 articles tagged with ‘clinical trials

HomeBlogTag: clinical trials
Retatrutide in Canada: Access, Trials, and Approval Timing
ScienceAugust 16, 2026

Retatrutide in Canada: Access, Trials, and Approval Timing

Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.

32 min read
RegulatoryMay 15, 2026

Novo Nordisk Presents Oral Semaglutide Phase 3a Trial Data at ADA

Novo Nordisk shared recent findings from two phase 3a trials of oral Semaglutide at the American Diabetes Association annual meeting. The drug reduced A1C levels and supported weight loss in type 2 diabetes patients compared to controls. Results from PIONEER 2 and PIONEER 4 trials showed significant improvements in blood sugar control and body weight.

3 min read
Atosiban Serves as Maintenance Therapy for Preterm Labor
RegulatoryMay 12, 2026

Atosiban Serves as Maintenance Therapy for Preterm Labor

Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its safety and role in reducing recurrent preterm labor episodes.

4 min read
Abaloparatide Reduces Osteoporotic Spine Fractures by 84%
Clinical TrialsMay 12, 2026

Abaloparatide Reduces Osteoporotic Spine Fractures by 84%

Abaloparatide, an analog of human PTHrP (1-34), shows strong potential in treating osteoporosis by boosting bone formation while limiting resorption. Animal studies confirm its ability to reverse bone loss in ovariectomy models, and a phase 3 trial revealed an 84% lower risk of new spine fractures at 43 months compared to placebo. This peptide offers advantages over traditional antiresorptives by improving bone strength and density.

3 min read

Your Cart

Your cart is empty

Browse our catalog to add research compounds.